{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:30:07Z","timestamp":1794591007113,"version":"4.9.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>Losartan was the ninth most prescribed drug in the United States in 2016, and several other angiotensin-II receptor blockers (ARBs) are widely prescribed. Since July 2018, &gt;2 dozen specific ARB products have been recalled owing to the presence of potentially carcinogenic nitrosamine impurities in selected lots. As is the case with all U.S. drug recalls, the ARB recalls have been voluntary on the part of the companies involved. In April 2019, the Food and Drug Administration categorized marketed ARB products with respect to nitrosamine impurities: (1) not present, (2) to be determined with no prior lots removed from the market (TBD), or (3) to be determined in the context of prior lots having been removed from the market (TBD*). The data were structured as hundreds of rows of products. Owing to the complexity of these data, more than a year into the recalls, it remains difficult for clinicians to understand which ARB products are free of impurities.<\/jats:p>","DOI":"10.1161\/hypertensionaha.119.13955","type":"journal-article","created":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T09:00:24Z","timestamp":1571648424000},"page":"1275-1278","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Current Status of Angiotensin Receptor Blocker Recalls"],"prefix":"10.1161","volume":"74","author":[{"given":"Pradeep Moon","family":"Gunasekaran","sequence":"first","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Internal Medicine (P.M.G., J.B.B.), University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine (G.M.C., V.B.), Stanford University School of Medicine, CA."},{"name":"Stanford Hypertension Center (G.M.C., V.B.), Stanford University School of Medicine, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Bhalla","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine (G.M.C., V.B.), Stanford University School of Medicine, CA."},{"name":"Stanford Hypertension Center (G.M.C., V.B.), Stanford University School of Medicine, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James Brian","family":"Byrd","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Department of Internal Medicine (P.M.G., J.B.B.), University of Michigan, Ann Arbor"},{"name":"University of Michigan Hypertension Center (J.B.B.), University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","unstructured":"Losartan Potassium ClinCalc DrugStats Database. Free U.S. Outpatient Drug Usage Statistics. https:\/\/clincalc.com\/DrugStats\/Drugs\/LosartanPotassium. Accessed June 3 2019."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1901657"},{"key":"e_1_3_4_4_2","unstructured":"Mulero A. FDA Works to Improve Voluntary Drug Recall Process. https:\/\/www.raps.org\/news-and-articles\/news-articles\/2019\/4\/fda-works-to-improve-voluntary-recall-processes. Accessed September 8 2019."},{"key":"e_1_3_4_5_2","unstructured":"Gibbons DC. Who can Recall what FDA\u2019s Mandatory Recall Authority is? A U.S. District Court Could Not\u2026. http:\/\/www.fdalawblog.net\/2014\/08\/who-can-recall-what-fdas-mandatory-recall-authority-is-a-us-district-court-could-not\/. Accessed September 8 2019."},{"key":"e_1_3_4_6_2","unstructured":"United Kingdom Medicines and Healthcare Products Regulatory Agency. Class 2 Medicines recall: Accord Healthcare Limited - Losartan Potassium 50mg Film-coated Tablets PL 20075\/0022 and Losartan Potassium 100mg Film-coated Tablets PL 20075\/0023. https:\/\/www.gov.uk\/drug-device-alerts\/class-2-medicines-recall-accord-healthcare-limited-losartan-potassium-50mg-film-coated-tablets-pl-20075-0022-and-losartan-potassium-100mg-film-coated-tablets-pl-20075-0023. Accessed September 7 2019."},{"key":"e_1_3_4_7_2","unstructured":"European Medicines Agency. Valsartan: Review of Impurities Extended to Other Sartan Medicines. https:\/\/www.ema.europa.eu\/en\/news\/valsartan-review-impurities-extended-other-sartan-medicines. Accessed September 8 2019."},{"key":"e_1_3_4_8_2","unstructured":"European Medicine Agency. Meeting Highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019. Accessed September 8 2019."},{"key":"e_1_3_4_9_2","unstructured":"European Directorate for the Quality of Medicines. Actions on CEPs. https:\/\/www.edqm.eu\/en\/actions-ceps#CEP%20suspension. Accessed September 8 2019."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042098618823458"},{"key":"e_1_3_4_11_2","unstructured":"United States Food and Drug Administration. Statement on the Agency\u2019s Ongoing Efforts to Resolve Safety Issue with ARB Medications. https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-agencys-ongoing-efforts-resolve-safety-issue-arb-medications. Accessed September 9 2019."},{"key":"e_1_3_4_12_2","unstructured":"United States Food and Drug Administration. Statement Alerting Patients and Health Care Professionals of NDMA found in Samples of Ranitidine. https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-alerting-patients-and-health-care-professionals-ndma-found-samples-ranitidine. Accessed September 16 2019."},{"key":"e_1_3_4_13_2","unstructured":"United States Food and Drug Administration. FDA\u2019s Assessment of Currently Marketed ARB Drug Products. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fdas-assessment-currently-marketed-arb-drug-products. Accessed June 7 2019."},{"key":"e_1_3_4_14_2","unstructured":"United States Food and Drug Administration. Drug Recalls. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/drug-recalls. Accessed September 9 2019."},{"key":"e_1_3_4_15_2","unstructured":"United States Food and Drug Administration. Search List of Recalled Angiotensin II Receptor Blockers (ARBs) including Valsartan Losartan and Irbesartan. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/search-list-recalled-angiotensin-ii-receptor-blockers-arbs-including-valsartan-losartan-and. Accessed July 16 2019."},{"key":"e_1_3_4_16_2","unstructured":"United States Food and Drug Administration. FDA Updates and Press Announcements on Angiotensin II Receptor Blocker (ARB) Recalls (Valsartan Losartan and Irbesartan). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan. Accessed July 16 2019."},{"key":"e_1_3_4_17_2","unstructured":"United States Food and Drug Administration. Enforcement Reports. https:\/\/www.accessdata.fda.gov\/scripts\/ires\/index.cfm#tabNav_advancedSearch. Accessed August 30 2019."}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.119.13955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:58:38Z","timestamp":1715594318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.119.13955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.119.13955"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.119.13955","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"2019-08-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}